HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- BCG: a real-world example of health care rationing
-
- Are there feasible alternatives to BCG for the effective treatment of bladder cancer?
- Patient access to new cancer treatments — an uncertain and fragile process John Sweetenham, MD, FRCP, FACP
- Ovarian cancer: Is this the beginning of the end? Michael J. Birrer, MD, PhD
- TAPUR study fulfilling need to better understand targeted therapies, ASCO’s Schilsky says
- Triplet therapy extends survival in BRAF V600E-mutant metastatic colorectal cancer
- Claudin-specific CAR T cells safe, effective in advanced gastric, pancreatic adenocarcinoma
- Radiotherapy plus ADT improves metastasis-free survival after radical prostatectomy
- Selinexor induces response among certain patients with recurrent glioblastoma
-
- Margetuximab improves PFS in HER2-positive metastatic breast cancer
- Pregnancy after breast cancer feasible, safe for BRCA carriers
- Pembrolizumab may provide alternative to chemotherapy for certain gastric, gastroesophageal junction cancers
- Laparoscopy as safe, effective as open surgery for colorectal liver metastases
- Ado-trastuzumab emtansine effective, safe in HER2-amplified salivary gland cancers
- National Lung Screening Trial publication yet to impact mortality rates
- Neoadjuvant atezolizumab shows promise in non-small cell lung cancer
- Continuous monitoring of circulating tumor DNA may guide treatment of advanced melanoma
-
- Minimally invasive surgery linked to higher recurrence risk in early cervical cancer
- Venetoclax plus cytarabine active, safe in relapsed, refractory pediatric acute myeloid leukemia
- Acalabrutinib plus obinutuzumab induces high rates of durable responses in chronic lymphocytic leukemia
- Breast cancer researcher to receive memorial lecture award
- ASH announces award recipients
- Vena cava filters after major trauma fail to reduce incidence of pulmonary embolism, death
- Despite ‘incremental’ progress, long-term survival rates ‘have not budged’ in glioblastoma
- Finasteride shows long-term safety for prostate cancer prevention
-
- Ibrutinib plus R-CHOP improves survival among younger patients with aggressive lymphoma subtype
- Checkpoint inhibitor rechallenge appears safe, with monitoring, after immune-related adverse events
- Chronic pain inhibits daily life for 1 in 6 cancer survivors
- FDA grants fast track designation to leronlimab for metastatic triple-negative breast cancer
- FDA rejects quizartinib for acute myeloid leukemia subtype
- FDA approves tumor-treating fields system for mesothelioma
- Prior authorization leads to ‘crippling delays and dysfunction’ in health care system
- St. Jude Children’s Research Hospital physician-scientist receives award
-